'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Ajanta Pharma has increased 3.71% to Rs 1146.13 crore. Operating profit margin has declined from 28.42% to 27.99%, leading to 2.15% rise in operating profit to Rs 320.83 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 21.94% to 17.85%. Purchase of finished goods cost rose from 3.61% to 6.67%. Employee cost increased from 21.24% to 22.53%. Other expenses rose from 24.38% to 25.69%.
Other income rose 123.99% to Rs 30.44 crore. PBIDT rose 7.21% to Rs 351.27 crore. Provision for interest rose 217.67% to Rs 7.91 crore.
PBDT rose 5.59% to Rs 343.36 crore. Provision for depreciation rose 4.99% to Rs 35.97 crore.
Profit before tax grew 5.66% to...
Pleaselogin & subscribe to view the full report.
More Reports
|
|